The unusual blood clotting disorder seems to have made its way back. Thirteen of the recipients of Johnson & Johnson’s one shot Covid-19 vaccine have been identified to be showcasing the symptoms. There is zero death toll, and no new cases have sprung up post the government’s interim halt for 11 days on J&J vaccine shots.
J&J Covid-19 Vaccine Associated With 13 Additional Cases Of Blood Clots
Twenty-eight people have been identified by the Centers for Disease Control and Prevention with the disorder. One that is termed as TTS or Thrombosis with thrombocytopenia syndrome.
The qualification procedure for the diagnosis states a blood clot to be mandatory. This is identified as “Thrombosis” with a location that is unconventional and could also include the brain. The other set of qualifiers states a mandatory low platelet count in the blood, which is regarded as “Thrombocytopenia”.
A combination that is a rarity. The occurrence amongst so many people in such a short span of two weeks post-vaccination has led the authorities to take note. One that indicates a probability of a causal association. This was brought to light by the deputy director of the Immunization Safety Office of the CDC, Dr. Tom Shimabukuro.
The total death count from the J&J one-shot vaccine has been three. At the same time, one of the recipients is still in an intensive care unit.
There are eight million Americans who have received the J&J vaccine jab before the interim halt was declared the past month. The identified TTS cases had received their jabs before the temporary pause, but the latest addition of 13 cases has been recent.
Since the resumption of the J&J single-shot vaccine on the 23rd of April, the dosage has been administered to 1 million people. While the highest risk group for the TTS syndrome, especially women under the age bracket of 50, has received 150,000 J&J vaccine shots. This is as per reports and data compiled by the CDC.
The 28 patients of the TTS syndrome constitute six men, up from the earlier count of one. The age range was counted to be 18 to 59, where the older patients have only cropped up recently.
The highest risk ratio for women is for the age range between the 30s to 40s. Shimabukuro also specified how there is no particular age bracket identified for men.
Six to fifteen days post-vaccination, the symptoms begin to show up. At the same time, the general side effects recede gradually.
The interim pause on the J&J vaccine shot as initiated by CDC was a part of a general warning for the vaccine recipients. The warning came in light of the TTS syndrome and its risks, thus alerting the doctors in its treatment of patients for TTS.
One that should not constitute any usage of heparin which is a commonly used drug administered for blood clots. This could lead the patients to an even worse condition.
The TTS cases have not been reported amongst any of the recipients of the Pfizer-BioNTech and the Moderna vaccines, which constitute a whopping 135 and 110 million doses, respectively. This is since the time of their inception and wide usage across the U.S. from December.
The Oxford University vaccine developed by AstraZeneca, available widely across Europe, also boasts of similar risks as caused by J&J. These two vaccines have been curated from a different technology than the other vaccinations. Shimabukuro mentions how the risks are not accessed as to which of the two poses more threat, AstraZeneca or the J&J shot.
The J&J vaccine has been considered the ideal one for several groups since it’s a single dosage shot. This is especially for reasons where people showcase hesitancy towards shots and are most unlikely to receive two doses. Hence the risks of TTS are constantly outnumbered by the benefits as deduced by an advisory group’s subcommittee.